Cheng J.-H.Huang A.-M.Hour T.-C.Yang S.-C.YEONG-SHIAU PULin C.-N.2021-02-022021-02-0220110223-5234https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952283054&doi=10.1016%2fj.ejmech.2011.01.043&partnerID=40&md5=ef3310a78dd5d1820c1d52767d2e67b0https://scholars.lib.ntu.edu.tw/handle/123456789/544427In an effort to develop novel antioxidant as anticancer agents, a series of xanthones were prepared. In vitro screening, the synthetic xanthones revealed significant inhibitory effects on xanthine oxidase and ABTS radical-cation scavenging activity. The selective compounds 2 and 8 induced an accumulation of NTUB1 cells in the G1 phase arrest and cellular apoptosis by the increase of ROS level. The combination of cisplatin and 2 significantly enhanced the cell death in NTUB1 cells. Compounds 2 and 8 did not show cytotoxic activity in selected concentrations against SV-HUC1 cells. The present results suggested that antioxidants 2 and 8 may be used as anticancer agent for enhancing the therapeutic efficacy of anticancer agents and to reduce their side effect. ? 2011 Elsevier Masson SAS. All rights reserved.Antioxidation; Cytotoxicity; Reactive oxygen species; Xanthone[SDGs]SDG32,2' azinobis(3 ethylbenzothiazoline 6 sulfonic acid); 3 [3 (4 methylpiperazino)propoxy]xanthone; 3 [3 (cyclohexylamino)propoxy] 6 hydroxyxanthone; 3 [3 (cyclopropylamino)propoxy] 6 hydroxyxanthone; 3 [3 (diethylamino)propoxy] 6 hydroxyxanthone; 3 [3 (diethylamino)propoxy]xanthone; 3 [3 (piperazino)propoxy]xanthone; 3 [3 (piperidin 1 yl)propoxy]xanthone; 3 [3 (pyrrolidin 1 yl)propoxy]xanthone; 3 hydroxy 6 [3 (methylpiperazylamino)propoxy]xanthone; 3 hydroxy 6 [3 (piperazino)propoxy]xanthone; 3 hydroxy 6 [3 (piperidin 1 yl)propoxy]xanthone; 3 hydroxy 6 [3 (pyrrolidin 1 yl)propoxy]xanthone; allopurinol; alpha tocopherol; cisplatin; reactive oxygen metabolite; unclassified drug; xanthine oxidase; xanthone derivative; antioxidant activity; apoptosis; article; cancer cell; cell cycle arrest; cell cycle G1 phase; cell cycle progression; cell death; controlled study; drug cytotoxicity; drug potentiation; drug screening; drug structure; drug synthesis; enzyme inhibition; epithelium cell; human; human cell; IC 50; in vitro study; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cisplatin; DNA Breaks; Dose-Response Relationship, Drug; Drug Discovery; Drug Synergism; Free Radical Scavengers; Humans; Reactive Oxygen Species; Structure-Activity Relationship; Xanthonesjournal article10.1016/j.ejmech.2011.01.043213455442-s2.0-79952283054